|1.||Wren, J A: 6 articles (08/2007 - 08/2007)|
|2.||Gossellin, J: 5 articles (08/2007 - 08/2007)|
|3.||Sunderland, S J: 5 articles (08/2007 - 08/2007)|
|4.||King, V L: 3 articles (08/2007 - 08/2007)|
|5.||Campbell, S L: 2 articles (08/2007 - 08/2007)|
|6.||Sherington, J: 2 articles (08/2007 - 08/2007)|
|7.||Rowan, T G: 2 articles (08/2007 - 08/2007)|
|8.||Eagleson, J S: 2 articles (08/2007 - 08/2007)|
|9.||Hickman, M A: 2 articles (08/2007 - 08/2007)|
|10.||Holden, S L: 1 article (11/2015)|
|1.||Body Weight (Weight, Body)
08/01/2007 - "Dirlotapide was safe and effective in the reduction and management of body weight in obese dogs."
08/01/2007 - "An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe."
08/01/2007 - "Food intake was adjusted to maintain body weight during adaptation, followed by pair-feeding placebo dogs the amount of food ingested by the dirlotapide dogs during the treatment period. "
08/01/2007 - "Dirlotapide produced the expected decrease in food intake and body weight (up to 20-40%) without ill effects. "
08/01/2007 - "Food intake and body weight increased when dirlotapide was discontinued. "
|2.||Weight Loss (Weight Reduction)
08/01/2007 - "Percentage weekly weight losses for dirlotapide were significantly greater than for placebo (P < or = 0.0002). "
08/01/2007 - "The clinical efficacy for weight loss and safety of dirlotapide in dogs were evaluated in two multi-centre studies with parallel designs. "
08/01/2007 - "In study A, weight losses for dirlotapide were 19.3% after 12 weeks of weight management and 16.7% (regain of 3.4%) by 8 weeks after dirlotapide was discontinued. "
08/01/2007 - "Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg, increased after 14 days to 0.1 (study B, label dose) or 0.2 mg/kg (study A) and then adjusted according to individual weight loss at 28-day intervals. "
08/01/2007 - "Dirlotapide-treated dogs showed mean weight loss of 15.9% (study A) and 14.0% (study B) by the end of weight loss phase (up to day 196). "
08/01/2007 - "In a margin-of-safety study, 38 overweight, neutered beagles were treated orally once daily for 3 months with dirlotapide at doses up to 0.5 mg/kg/day (six dogs), 1.5 mg/kg/day (12 dogs) and 2.5 mg/kg/day (six dogs). "
08/01/2007 - "Overweight, adult dogs (n = 245) of various breeds were randomized to treatment with dirlotapide or placebo in a 2:1 ratio. "
08/01/2007 - "Dirlotapide was found to be clinically safe and effective in the reduction of body weight in overweight dogs."
08/01/2007 - "The effects of dirlotapide on body weight (BW) reduction were investigated in overweight Labradors in two parallel-design studies. "
08/01/2007 - "Evaluation of dirlotapide for sustained weight loss in overweight Labrador retrievers."
08/01/2007 - "Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America. "
08/01/2007 - "Dirlotapide: a review of its properties and role in the management of obesity in dogs."
08/01/2007 - "Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs. "
04/01/2007 - "In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity."
08/01/2007 - "In both studies, sporadic emesis and loose stools were observed in both placebo and dirlotapide-treated dogs. "
08/01/2007 - "Emesis and diarrhoea were experienced in both treatments but were more frequent with dirlotapide; resolution was spontaneous. "
08/01/2007 - "The initial dirlotapide dosage of 0.5 mg/kg (10 times the initial label dose) resulted in a high rate of weight loss (3.3% weekly) and anorexia, emesis, and loose stools for some dogs. "
|2.||microsomal triglyceride transfer protein